Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds.

Drugs currently available for leishmaniasis treatment often show parasite resistance, highly toxic side effects and prohibitive costs commonly incompatible with patients from the tropical endemic countries. In this sense, there is an urgent need for new drugs as a treatment solution for this neglect...

Full description

Bibliographic Details
Main Authors: Jair L Siqueira-Neto, Ok-Ryul Song, Hyunrim Oh, Jeong-Hun Sohn, Gyongseon Yang, Jiyoun Nam, Jiyeon Jang, Jonathan Cechetto, Chang Bok Lee, Seunghyun Moon, Auguste Genovesio, Eric Chatelain, Thierry Christophe, Lucio H Freitas-Junior
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-01-01
Series:PLoS Neglected Tropical Diseases
Online Access:http://europepmc.org/articles/PMC2864270?pdf=render